PHARMAPROGRAMS has launched the new Medicinal Cannabis Medicines Portal (MCMP) www.mcmp.com.au, designed to provide a streamlined process for medicinal cannabis prescribing and dispensing between health professionals and manufacturers.
The MCMP will ensure a continuity of care between patients, carers, and their existing doctors and pharmacists, PharmaPrograms says.
The MCMP is open to all manufacturers of medicinal cannabis and will ensure appropriate supply of Medicinal Cannabis via the Therapeutic Goods Administration's (TGA's) Special Access Scheme (SAS).
Medicinal cannabis from selected multiple manufacturers will be distributed via the trusted community pharmacy network in Australia.
The foundation company participants in the portal are Cann Group Limited & The Hydroponics Company (Canndeo Limited).
PharmaPrograms systems architect and pharmacist Kos Sclavos AM believes that the MCMP will ensure that a greater number of health professionals will be able to work together to support patients and carers who require access to medicinal cannabis. Health Professionals will be supported through the regulatory requirements.
"The IT enabled system will support patients and carers, optimising Quality Use of Medicines (QUM). Initially, supply will focus on selected manufacturers approved to import bulk supplies of medicinal cannabis products, under the TGA SAS (Category B) or Approved Prescribers schemes," Sclavos said.
Cann Group ceo Peter Crock said, "The MCMP will provide a much-needed channel for patients to access product while also bridging the gap with health professionals seeking the information to allow appropriate advice and prescription."
The MCMP provides resources to support healthcare professionals ready to use the system once the portal goes live in late Oct.
The above article was sent to subscribers in Pharmacy Daily's issue from 12 Sep 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 12 Sep 17
